{"id":"tafamidis-meglumine-soft-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2105675","moleculeType":"Small molecule","molecularWeight":"503.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafamidis binds to transthyretin and increases its kinetic stability, preventing the formation of amyloid deposits that cause tissue damage. By stabilizing the native tetrameric form of TTR, it slows or halts the progression of transthyretin amyloidosis, a progressive neurodegenerative and/or cardiomyopathic disease.","oneSentence":"Tafamidis stabilizes transthyretin (TTR) protein tetramers, preventing their dissociation and misfolding into amyloid fibrils.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:55.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transthyretin amyloidosis (ATTR amyloidosis), including hereditary ATTR (hATTR) with polyneuropathy"},{"name":"Wild-type transthyretin amyloidosis (wtATTR)"}]},"trialDetails":[{"nctId":"NCT06940336","phase":"PHASE4","title":"To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-19","conditions":"Transthyretin Amyloid Polyneuropathy","enrollment":15},{"nctId":"NCT02791230","phase":"PHASE3","title":"Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-06-13","conditions":"Transthyretin (TTR) Amyloid Cardiomyopathy","enrollment":1733},{"nctId":"NCT04575116","phase":"PHASE1","title":"A Study to Determine the Bioequivalence of Two Doses of Tafamidis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-17","conditions":"Healthy","enrollment":23},{"nctId":"NCT00935012","phase":"PHASE3","title":"Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-09-30","conditions":"ATTR-CM, TTR-CM","enrollment":31},{"nctId":"NCT01994889","phase":"PHASE3","title":"Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-09","conditions":"Transthyretin (TTR) Amyloid Cardiomyopathy","enrollment":441},{"nctId":"NCT03662191","phase":"PHASE1","title":"Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-28","conditions":"Healthy Volunteers","enrollment":9},{"nctId":"NCT03266705","phase":"PHASE1","title":"A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-20","conditions":"Healthy","enrollment":30},{"nctId":"NCT03280173","phase":"PHASE1","title":"A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-09-29","conditions":"Healthy","enrollment":18},{"nctId":"NCT02746926","phase":"PHASE1","title":"A Study Comparing Amounts of Tafamidis (PF-06291826) in the Blood Without Food in Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04-29","conditions":"Healthy","enrollment":12},{"nctId":"NCT02697864","phase":"PHASE1","title":"A Study Comparing Amounts of Tafamidis In The Blood Without Food","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04","conditions":"Healthy","enrollment":12},{"nctId":"NCT02534740","phase":"PHASE1","title":"A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT02189330","phase":"PHASE1","title":"A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT00630864","phase":"PHASE2","title":"The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Transthyretin-associated Amyloidosis With Polyneuropathy","enrollment":21},{"nctId":"NCT00694161","phase":"PHASE2","title":"The Effects Of Fx-1006A On Transthyretin Stabilization And Clinical Outcome Measures In Patients With V122I Or Wild-Type TTR Amyloid Cardiomyopathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-08","conditions":"Cardiomyopathy","enrollment":35},{"nctId":"NCT00791492","phase":"PHASE2, PHASE3","title":"An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-07","conditions":"Familial Amyloid Polyneuropathy, ATTR-PN","enrollment":86},{"nctId":"NCT01369836","phase":"PHASE1","title":"Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Healthy","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Tafamidis Meglumine Soft Capsules","genericName":"Tafamidis Meglumine Soft Capsules","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafamidis stabilizes transthyretin (TTR) protein tetramers, preventing their dissociation and misfolding into amyloid fibrils. Used for Transthyretin amyloidosis (ATTR amyloidosis), including hereditary ATTR (hATTR) with polyneuropathy, Wild-type transthyretin amyloidosis (wtATTR).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}